Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Verastem Oncology

< Previous 1 2 3 4 Next >
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Tickers VSTM
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces $75 million Private Placement
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
From Verastem Oncology
Via Business Wire
Tickers VSTM
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
From Verastem Oncology
Via Business Wire
Tickers VSTM
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.